PolyPid submits D-PLEX100 NDA to FDA under rolling review

PolyPid - FDA Decision on D-Plex100 Expected in Q1 2027 Under Pdufa Timeline

PolyPid Completes New Drug Application Submission to FDA for D-Plex₁₀₀

PolyPid management attends Craig-Hallum institutional investor conference investor meetings

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

PolyPid’s Earnings Call Signals Tightrope to Approval

PolyPid reports Q1 EPS (35c), consensus (43c)

PolyPid Ltd reports results for the quarter ended December 31 - Earnings Summary

PolyPid Advances D-PLEX₁₀₀ Toward FDA Review as Q1 2026 Loss Narrows and Debt Is Retired

PolyPid Q1 FY26 net loss narrows 7.61% to $7.7 million

PolyPid Q1 EPS $(0.35) Beats $(0.43) Estimate

PolyPid Ltd - U.S. Commercial Partnership Discussions for D-Plex100 in Late Stages

Press Release: PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

Calendar of U.S. Earnings Expected in the Week Ahead

PolyPid Ltd expected to post a loss of 43 cents a share - Earnings Preview

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

Roth MKM Remains a Buy on PolyPid (PYPD)

PolyPid says SHIELD II data show D-PLEX100 doxycycline release lasts up to 32 days

PolyPid starts trading on Frankfurt Stock Exchange under 2PV, adding to Nasdaq listing